clinical trial · NCT07489716
A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·phase2·not yet recruiting·n = 90
Non-Small Cell Lung CancerSHR-1826
brief summary
This study is a single-arm, open-label, multicenter phase II clinical trial aimed at evaluating the efficacy, safety, and pharmacokinetics of SHR-1826 in treating locally advanced or metastatic non-small cell lung cancer . The recommended dose of SHR-1826 was administered via intravenous infusion once every 3 weeks (Q3W), with each treatment cycle lasting 21 days until meeting protocol-defined treatment discontinuation criteria.
started
Apr 1, 2026
primary completion
Aug 1, 2028
completion
Dec 1, 2028
last updated
Mar 24, 2026
official title
A Phase II Clinical Study on the Efficacy, Safety, and Pharmacokinetics of SHR-1826 for Injection in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol